Skip To Main Content
Wanying Shen on Muck Rack

Wanying Shen

As seen in: MDPI, Dove Medical Press, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wanying

Contact Wanying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma

|
By Wanying Shen, Yujie Chen, Pan Lei, Marisela Sheldon
| Texas Medical Center
Abstract Liver cancer is a life-threatening disease, and its incidence is increasing globally. The most common form of liver cancer is hepatocellular carcinoma (HCC). Approximately half of patients with HCC, especially those at advanced disease stages, receive systemic therapies, including the tyrosine kinase inhibitors sorafenib and lenvatinib. Over the past few years, immune checkpoint inhibitors (ICIs) have changed the landscape of HCC treatment.
Open in Who Shared Issue with article?

Cardiovascular Disease Burden Attributable to High Sodium Intake in China: A Longitudinal Study from 1990 to 2019

|
By Liying Jiang, Wanying Shen, Anqi Wang, Haiqin Fang
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (566) Issue with article?

KRAS inhibitor adagrasib in rats using UPLC-MS/MS

|
By Pan Lei, Wanying Shen, Huijuan Tang, Guoyi Chen
| Dove Medical Press
Back to Journals » Drug Design, Development and Therapy » Volume 18 Authors Lei P, Shen W, Tang H, You L, Chen G, Tang Y, Lu W Received 26 August 2023 Accepted for publication 21 December 2023 Published 5 January 2024 Volume 2024:18 Pages 1—12 DOI https://doi.org/10.2147/DDDT.S437293 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Manfred Ogris Pan Lei,1,2 Wanying Shen,2 Huijuan Tang,2 Li You,2 Guoyi Chen,2...
Open in Who Shared Issue with article?
See all 3 articles